Gilead

Manufacturer Gilead questions Solidarity Trial’s results, says it was disappointed at the new WHO guideline

Remdesivir is in high demand after the medicine helped to shorten hospital recovery times in a clinical trial

Gilead’s shares jumped nearly 10% following a media report detailing encouraging partial data from trials

Gilead had said the drug helped improve outcomes for patients with coronavirus

In Gilead's study, 62% of patients treated early were discharged from the hospital